Semaglutide

Disappointing GLP-1 Results in Alzheimer’s Trial: Underscores Promise (and Limits) of Single-Agent Approaches

GLP-1s and Alzheimer's

Scientists have studied Alzheimer’s disease for over a century, since Alois Alzheimer’s initial description of brain abnormalities in a patient with presenile dementia. Today, amyloid‑beta plaques and tau tangles are recognized as hallmarks of the disease, though its causes are complex and multifactorial.

Read More

Subscribe to Our Blog

Be the first to receive exclusive life science articles directly to your inbox. Monthly news articles include interviews, webinars and insights from life science experts.

The information you provide will be used in accordance with the terms of our privacy policy.